BioInvent International AB · OMXSTO:BINV
BioInvent International AB — Redeye Investor Forum Stockholm 2013
20 slides from BioInvent International AB's conference presentation, Feb 26, 2013
Slide 1: Antibodies for Life - Management presentation
- Antibodies for Life - Management presentation February 26, 2013 Cristina Glad, President and CEO
Slide 2: Forward-looking statements
Forward-looking statements This presentation includes forward-looking statements based on the beliefs and expectations of the Company. These statements are based on the Company’s current plans, estimates and projections, as well as of expectations of external conditions and events. All such forward-
Slide 3: BioInvent at a glance
BioInvent at a glance Proprietary discovery platform n-CoDeR® human antibody library F.I.R.S.T™ antibody screening technology Clinical manufacturing capacity Strategic focus on haematological cancer Three product candidates under development Business model for self-financing Revenues from
Slide 4: Monoclonal antibodies a sweet spot in pharma
Monoclonal antibodies a sweet spot in pharma Fastest growing segment within Sales of therapeutic antibodies pharma market (CAGR of 11%, $ bln antibody market 2013 US$ 60bln) 70 Addresses unmet need in blockbuster 60 indications such as oncology and 50 inflammation 40 Shows lower attrition and
Slide 5: Proprietary Programs
- Antibodies for Life - Proprietary Programs 5
Slide 6: BioInvent Proprietary Pipeline
BioInvent Proprietary Pipeline Preclinical Project Indication Research Phase I Phase I/II development Multiple Results BI-505 2013 Myeloma Jan 2013 Hematological Toxicology ADC-1013 malignancies 2013 Hematological Toxicology BI-1206 malignancies 2014 Tumour associated Several cancers macrophages 6
Slide 7: BI-505 to treat Multiple Myeloma
BI-505 to treat Multiple Myeloma Fully human antibody developed for treatment for multiple myeloma Indication (cancer of antibody producing B cells) Forces cancer cells into “suicide mode” (induces programmed cell Mode of action death) and engages immune-effector cells Targets Inter-Cellular A
Slide 8: BI-505: Translating solid science to the clinic
BI-505: Translating solid science to the clinic ICAM-1 is highly and selectively expressed in Multiple Myeloma ICAM-1 expression in Multiple Myeloma 35 patients with advance stage of multiple myeloma treated with doses ranging from 0.0004 – 20 mg/kg Phase I Preliminary results show stable diseas
Slide 9: BI-505: Strategic options in Multiple Myeloma
BI-505: Strategic options in Multiple Myeloma Option 1 – Progressed disease Strategic considerations Option 2 – Maintenance Area of high attention Combination with newer agents: from big pharma Single-agent activity: In relapsed patients companies In remitted patients First-line indication
Slide 10: BI-505 progressing to new clinical study
BI-505 progressing to new clinical study Previously untreated patients Population Diagnosed as asymptomatic Also referred to smoldering multiple myeloma (SMM) Minor patient population at centers in Scandinavia Design Registering level of urine and plasma M proteins in patients SMM charac
Slide 11: ADC-1013 to treat Haematological Malignancies
ADC-1013 to treat Haematological Malignancies Fully human antibody activating the immune system (particularly Description dendritic cells) to kill cancer cells Immunostimulatory receptor agonist Mode of action Intra-tumoral administration for enhanced efficacy and reduced risk of side effects
Slide 12: BI-1206 in Non-Hodgkin Lymphoma
BI-1206 in Non-Hodgkin Lymphoma Fully human antibody boosting antibody therapeutics such as: Description Rituxan (haematological malignancies) Herceptin (breast cancer) Anti-CD32b antagonistic antibody Mode of action Blocks rituximab internalisation -- >improves rituximab efficacy Target
Slide 13: Partnered Programs
- Antibodies for Life - Partnered Programs 13
Slide 14: Revenue Model Partnered Programs
Revenue Model Partnered Programs n-CoDeR & F.I.R.S.T BioInvent or Partner Lead candidate Research Funding Programs fully funded by partner License fees Milestones Up to $ 15m in future milestone payments per program Royalties Royalties on all product sales Payments increasing as prod
Slide 15: F.I.R.S.T - New horizons in antibody discovery
F.I.R.S.TTM – New horizons in antibody discovery Patient materials n-CoDeR® Function-first screening Based on BioInvent’s proprietary n- Target identification CoDeR® library Screening malignant primary cell lines for previously unknown targets High-activity antibodies defined in early stages o
Slide 16: Development Status Partnered Programs
Development Status Partnered Programs Partner The collaboration Access to n-CoDeR under a license with Product License options BioInvent has selected one of the Product Candidates under development Access to n-CoDeR under a license with Product License options BioInvent commissioned to selec
Slide 17: Key Financials
- Antibodies for Life - Key Financials 17
Slide 18: Key Financial Figures
Key Financial Figures Jan-Dec Jan-Dec SEK mln 2012 2011 Non-recurring costs of Net revenues 43 125 SEK 31m in 2012 Revenues in 2011 incl. Sales and administrative costs -39 -33 SEK 108m milestone Research and development costs -207 -164 payments Major clinical Operating profit/loss -191 -163 c
Slide 19: Bringing on the future!
Bringing on the future ! Implementing a self-financing business model BI-505 progressing in clinical development Enhanced technology offer Increased focus on new deals Established partnerships advancing Two new product candidates in preclinical development 19
Slide 20: Thank you!
- Antibodies for Life - Thank you ! 20
BioInvent International — Redeye Investor Forum Stockholm 2013 on 6ix